Appearing as a noteworthy breakthrough in the struggle against obesity, the drug is generating considerable interest . This treatment combines properties of two established GLP-1 receptor agonists, semaglutide , with an new glucose-dependent peptide component. Early patient findings have demonstrated impressive weight decrease in people with a … Read More